Abstracts tagged "risk and tobacco use"

Abstract Number: 124 • 2017 ACR/ARHP Annual Meeting
Smoking and Rheumatoid Arthritis Susceptibility; Quantification of the Impact of Cumulative Dose, Frequency and Duration of Smoking, and Smoking Cessation
Lars Alfredsson¹, Anna Karin Hedström², Camilla Bengtsson³ and Lars Klareskog⁴, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Smoking is one of the most established risk factors for rheumatoid arthritis (RA). The aim of this study was to estimate how age at…
Abstract Number: 125 • 2017 ACR/ARHP Annual Meeting
Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study
Lars Alfredsson¹, Anna Karin Hedström² and Lars Klareskog³, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Smoking has consistently been associated with increased risk of developing rheumatoid arthritis (RA). We investigated the influence of passive smoking on the risk of…
Abstract Number: 2298 • 2016 ACR/ARHP Annual Meeting
Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample
Dilli Poudel¹, Paras Karmacharya¹ and Anthony Donato², ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA
Background/Purpose: Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous anti-oxidant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].